

Next Generation of Liposomal Delivery for Cannabidiol From a Hemp Extract: A Safety Study

By Emek Blair, PhD, CELLg8 and Valimenta Labs, Fort Collins, Colorado

Abstract

A human clinical safety study examined the alterations in the blood profiles of 10 healthy adults before and after taking CELLg8™ Hemp—an advanced liposomal cannabinoid preparation standardized for cannabidiol—daily for 30 days. Primary outcome measures were the comprehensive metabolic panel and complete blood count. Results showed that of 340 blood tests administered, 339 improved or remained the same at day 30. One patient showed an increase in absolute eosinophil or neutrophil count from 319 to 573 cells/μL (normal range, 15-500 cells/μL). Furthermore, all 5 individuals who had high glucose levels at baseline showed normal levels on day 30 of liposomal cannabidiol treatment. In conclusion, this study demonstrated the safety of CELLg8™ Hemp and the potential efficacy of this preparation to lower fasting blood glucose levels.

“Our results are very promising and additional work is in the planning stages to further delineate the mechanism of action of CBD on glucose levels, and to confirm the present findings.”

—Emek Blair, PhD

Introduction

Although there are numerous mouse and animal studies on cannabidiol (CBD), there are limited human studies and no credible randomized controlled human safety studies in the literature.¹ To our knowledge, this is the first human study to assess the safety of CBD in a liposomal CBD preparation. The purpose of the study was to investigate the safety (ie, lack of negative effects on blood profiles) of taking a liposomal CBD product for 30 days. Puffin Hemp (<http://www.puffinhemp.com>) has a patent-pending proprietary liposome manufacturing technology, CELLg8™, that is used to make highly bioavailable CBD preparations. Additionally, this product uses natural liposomes to

increase the amount of hemp actives that quickly enter the bloodstream, which is the subject of a paper to be published in the next issue of *American Journal of Endocannabinoid Medicine*.

Methods

Materials

Liposomal CELLg8 CBD, derived from industrial hemp, was provided from Puffin Hemp's stock production. Each 1 mL contains 10 mg of CBD from full-spectrum hemp extract, lipids derived from non-GMO sunflowers, tetrahydrocannabinol <0.05%, water <1 microS/cm, with natural plant extracts used to mask the hemp flavor for compliance.

Study Population

Participants were recruited from the general population in Colorado using the following inclusion criteria:

- 25 to 70 years of age
- Ability to read and sign the informed consent and complete the protocol
- Ability to comply with study requirements and study schedule
- Not taking a CBD product at baseline
- In good general health

Exclusion criteria included the inability to complete the protocol and the presence of a terminal illness.

Study Design

The study included 10 healthy individuals. At the first visit, the participants were given a 1-month supply of liposomal CBD, and after fasting for 8 hours, completed a baseline blood draw to assess comprehensive metabolic panel (CMP; 16 measures) and a complete blood count (CBC; 18 measures). After taking 10 mg of liposomal CBD daily for 30 days without any lifestyle changes, participants returned for a repeat blood draw. CMP and CBC measures from both time points were compared.

Results

Of 340 blood tests that were administered (on the CMP and CBC combined), 339 remained relatively the same or

Table 1. Excerpt of Comprehensive Metabolic Panel From Baseline to Day 30 of Taking Liposomal CBD

Participant	Test	Baseline value	Day 30 value	Normal range	Change from baseline
2	BUN	28 mg/dL	28 mg/dL	7–25 mg/dL	H to H
3	Glucose	100 mg/dL	88 mg/dL	65–99 mg/dL	H to N
3	ALT	30 U/L	20 U/L	6–29 U/L	H to N
4	Glucose	103 mg/dL	87 mg/dL	65–99 mg/dL	H to N
4	CO ₂	30 mmol/L	31 mmol/L	18–30 mmol/L	N to H
5	Glucose	106 mg/dL	94 mg/dL	65–99 mg/dL	H to N
7	Glucose	109 mg/dL	91 mg/dL	65–99 mg/dL	H to N
8	Glucose	141 mg/dL	99 mg/dL	65–99 mg/dL	H to N
10	Creatinine	1.12 mg/dL	1.17 mg/dL	0.5–99 mg/dL	H to H
10	Bilirubin	1.3 mg/dL	1.2 mg/dL	0.5–1.2 mg/dL	H to N

ALT, alanine transaminase; BUN, blood urea nitrogen; CBD, cannabidiol; CO₂, carbon dioxide; H, high; L, low; N, normal.

Table 2. Complete Blood Cell Count Measures From Baseline to Day 30 of Taking Liposomal CBD

Participant	Test	Baseline value	Day 30 value	Normal range	Change from baseline
1	RBC count	3.95 million/μL	4.28 million/μL	3.96–5.31 million/μL	L to N
2	Hematocrit	39%	45.6%	41.5%–53.8%	L to N
2	Absolute EOC or absolute neutrophils	319 cells/μL	573 cells/μL	15–500 cells/μL	N to H
4	Hb	18.5 g/dL	18.4 g/dL	13.7–17.7 g/dL	H to H
4	MPV	13.2 f/L	13.5 f/L	7.5–12.5 f/L	H to H
6	Hb	11.7 g/dL	11.6 g/d	13.7–17.7 g/dL	L to L
6	Hematocrit	36%	35.9%	41.5%–53.8%	L to L
6	MCH	26.52 pg	26.6 pg	27–33 pg	L to L
6	RDW	15.6%	15.9%	11%–15%	H to H
9	Absolute lymphocytes	617 cells/μL	536 cells/μL	850–3900 cells/μL	L to L
9	Absolute EOC	9 cells/μL	8 cells/μL	15–500 cells/μL	L to L

EOC, eosinophil count; H, high; Hb, hemoglobin; L, low; MCH, mean corpuscular hemoglobin; MPV, mean plasma volume; N, normal; RBC, red blood cell; RDW, red cell distribution width.

improved after 30 days of daily consumption of liposomal CBD. Additionally, 7 of the 10 participants in this study who had at least 1 CMP or CBC measure that was above or below the reference range at baseline showed normal levels after taking liposomal CBD for 30 days.

Two participants had a measure that changed from normal to high at day 30. Participant 4 showed a small increase in blood carbon dioxide that was not considered clinically significant (ie, an increase from 30 to 31 mmol/L that was 1 mmol/L over the normal range; see Table 1). Participant 2 experienced an increase in absolute eosinophil or neutrophil count to 73 cells/μL higher than the normal range (Table 2).

On the CMP measures, 7 of 10 of the measures that were above or below the normal range at baseline normalized after taking liposomal CBD for 30 days (Table 1). A striking improvement in fasting glucose levels was observed in all 5 participants who had above-average glucose levels at baseline. Additionally, 1 of the participants initially had out-of-range alanine transaminase and bilirubin assay values that were normalized after taking liposomal CBD for 30 days. Two of the participants who had higher-than-normal creatinine levels at baseline remained in the high range at day 30, and 1 participant with a high range blood urea nitrogen level at baseline remained in the high range at day 30.

► continued on page 22

SAFETY

continued from page 21

On the CBC measure, 5 participants had out-of-range values at baseline (Table 2). The red blood cell count for 1 participant and the hematocrit value for 1 participant normalized. The other values that were out of range did not normalize, but did not worsen.

Discussion

Results of this study demonstrated that no deleterious effects of liposomal CBD on CMP or CBC measures were found in any of the 10 participants after taking this product on a daily basis for 30 days. Additionally, 10 measures were normalized at day 30. The findings suggest that liposomal CBD, when used in this healthy population, is safe.

Additionally, all participants reported satisfaction with the liposomal CBD formulation and said that they would like to continue taking this product in the future.

It is believed that CBD and other cannabinoids are nontoxic, with no known fatal overdose levels reported.¹ Results of this study further substantiate this idea.

In the present study, 8 of 10 participants maintained normal bilirubin levels; whereas 1 had their bilirubin normalize over the 30-day period. In contrast, a recent study found hepatotoxicity of CBD in a mouse model.² The present findings are in line with other research suggesting that CBD may protect the liver from alcohol-induced damage³ and ischemia reperfusion injury.⁴

Although all the markers remained relatively constant over time, blood glucose was the exception. All 5 participants who exhibited a high glucose level at baseline showed normal levels after taking liposomal CBD for 30 days. Mouse studies have shown that CBD reduced pancreatic inflammation in a mouse model.⁵ Data from the National Health and Nutrition Examination Survey found that current marijuana users had lower fasting insulin levels and lower homeostasis model assessment of insulin resistance than non- or past users.⁷ Our results are very promising and additional work is in the planning stages to further delineate the mechanism of action of CBD on glucose levels, and to confirm the present findings.

Additionally, data from a mouse model of nonobese diabetic mice suggests a positive or neutral effect of cannabinoid ingestion on diabetes markers.⁷ Furthermore, a small number of controlled clinical trials in humans suggests that cannabinoids may be beneficial in controlling blood sugar,

pain, or other symptoms associated with diabetes, but more studies are required to confirm these findings.⁷ Based on the current animal research, CBD; peripheral blockade of the CB₁ receptor; and increased activity of CB₂, GPR55, or GPR119 have shown promise in the treatment of diabetes, but require further testing in humans. Many studies have demonstrated a connection between chronic inflammation and insulin resistance, indicating a potential role for CBD in affecting these markers. Future work in this area is recommended.

For the normalization in blood urea nitrogen and creatinine, the sample size is too small to draw any conclusions as there was no significant and obvious change. For the blood measures that remained in the high or low range, these measures were not significantly out of range or not markedly altered after consuming liposomal CBD.

Conclusion

Liposomal CBD was well tolerated in this small case series, improved blood measures in some cases, and was considered safe. It is recommended that the beneficial effects of liposomal CBD on blood glucose levels be explored further in future studies.

References

1. Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA. Safety and side effects of cannabidiol, a Cannabis sativa constituent. *Curr Drug Saf.* 2011;6(4):237-249.
2. Ewing LE, Skinner CM, Quick CM. Hepatotoxicity of a cannabidiol-rich cannabis extract in the mouse model. *Molecules.* 2019;24(9). pii: E1694.
3. Wang Y, Mukhopadhyay P, Cao Z, et al. Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. *Sci Rep.* 2017;7(1):12064.
4. Mukhopadhyay P, Rajesh M, Horváth B, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. *Free Radic Biol Med.* 2011;50(10):1368-1381.
5. Lehmann C, Fisher NB, Tugwell B, Szczesniak A, Kelly M, Zhou J. Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. *Clin Hemorheol Microcirc.* 2016;64(4):655-662.
6. Ngueta G, Ndjaboue R. Lifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults [Epub ahead of print]. *J Diabetes.* 2019 Jun 1. doi: 10.1111/1753-0407.12958.
7. Weiss L, Zeira M, Reich S, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. *Autoimmunity.* 2006;39(2):143-151.


Dr. Blair is the owner of Puffin Hemp and funded the research.

Please visit www.ajendomed.com for supplemental data related to this article.

American Journal of Endocannabinoid Medicine

science • knowledge • research

Volume 1 • Issue 1



Positive Autism Intervention With Cannabidiol: A Case Study

**Next Generation of Liposomal
Delivery for Cannabidiol From a
Hemp Extract: A Safety Study**

**The Endocannabinoid
System:
A Therapeutic Target**

**Dosing Strategies for
Medical Cannabis**